Lymphoma Testing Sample type required Turnaround times: G-banded analysis (test performed on fixed cultured cells) Bone marrow (Lithium Heparin– 5ml) Diagnostic 21 days – Peripheral blood (Lithium Heparin-5ml) Follow-up 21 days – Fluorescence in situ hybridisation (FISH) (test performed on fixed cultured cells /smear slides) Bone marrow (Lithium Heparin– 5ml) Diagnostic 21 days – Non Hodgkin Lymphoma (NHL) Peripheral blood (Lithium Heparin-5ml) Follow-up 21 days IGH – T-cell Lymphomas Solid tissue biopsy (in saline) TRAD,TRB,TRG,TCL1 Follicular Lymphoma (IGH-MYC IF *CSF Cytospin slides IGH-BCL2 ?TRANSFORMING) *FFPE tissue section slides (2-4uM) Burkitts/Diffuse Large B-cell Lymphoma (DLBCL) IGH-MYC/CEP8, MYC, BCL6, IGH-BCL2 Touch imprint slides Post Transplant Lymphoproliferative Disorders IGH (PTLD) Anaplastic Large Cell Lymphoma ALK Chronic Lymphocytic Leukaemia (CLL) ATM/TP53, CEP12/13q Mantle Cell Lymphoma (MCL) IGH-CCND1 Mutation detection by Sanger sequencing (test performed on DNA) Bone marrow (EDTA 2-5ml) Diagnostic 28 days – – Peripheral blood (EDTA 2-5ml) Follow-up 28 days TP53 – – Current trials participation None. Waldenstroms macroglobulinaemia Testing Sample type required Turnaround times: Mutation detection by Allele specific real time PCR (AS qPCR) (test performed on DNA) Bone marrow (EDTA 2-5ml) Diagnostic 28 days – – Follow-up 28 days – MYD88 p.Leu265Pro – p.S338* – Mutation detection by Sanger sequencing (test performed on DNA) Bone marrow (EDTA 2-5ml) Diagnostic 28 days – – Follow-up 28 days CXCR4 (hotspot) – Current trials participation
Lymphoma Testing Sample type required Turnaround times: G-banded analysis (test performed on fixed cultured cells) Bone marrow (Lithium Heparin– 5ml) Peripheral blood (Lithium Heparin-5ml) Diagnostic – 21 days Follow-up – 21 days Fluorescence in situ hybridisation (FISH) (test performed on fixed cultured cells /smear slides) Bone marrow (Lithium Heparin– 5ml) Peripheral blood (Lithium Heparin-5ml) Solid tissue biopsy (in saline) *CSF Cytospin slides *FFPE tissue section slides (2-4uM) Touch imprint slides Diagnostic – 21 days Follow-up – 21 days Non Hodgkin Lymphoma (NHL) IGH T-cell Lymphomas TRAD,TRB,TRG,TCL1 Follicular Lymphoma IGH-BCL2 (IGH-MYC IF ?TRANSFORMING) Burkitts/Diffuse Large B-cell Lymphoma (DLBCL) IGH-MYC/CEP8, MYC, BCL6, IGH-BCL2 Post Transplant Lymphoproliferative Disorders (PTLD) IGH Anaplastic Large Cell Lymphoma ALK Chronic Lymphocytic Leukaemia (CLL) ATM/TP53, CEP12/13q Mantle Cell Lymphoma (MCL) IGH-CCND1 Mutation detection by Sanger sequencing (test performed on DNA) Bone marrow (EDTA – 2-5ml) Peripheral blood (EDTA – 2-5ml) Diagnostic – 28 days Follow-up – 28 days TP53 Current trials participation None. Waldenstroms macroglobulinaemia Testing Sample type required Turnaround times: Mutation detection by Allele specific real time PCR (AS qPCR) (test performed on DNA) Bone marrow (EDTA – 2-5ml) Diagnostic – 28 days Follow-up – 28 days MYD88 – p.Leu265Pro – p.S338* Mutation detection by Sanger sequencing (test performed on DNA) Bone marrow (EDTA – 2-5ml) Diagnostic – 28 days Follow-up – 28 days CXCR4 (hotspot) Current trials participation
Test%20directory%20SIHMDS-AG%20June%202018.pdf.docx